

Lexeo Therapeutics stock jumps as LX2006 pivotal trial moves forward, with SUNRISE-FA 2 enrollment set to begin in June 2026.
You can purchase shares of Lexeo Therapeutics (NASDAQ:LXEO) through any online brokerage.
Other companies in Lexeo Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Lexeo Therapeutics has a consensus price target of $19.08.
The stock price for Lexeo Therapeutics (NASDAQ: LXEO) is $3.23 last updated November 4, 2026 at 4:00 PM EST.
There are no upcoming dividends for Lexeo Therapeutics.
Lexeo Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Lexeo Therapeutics.
Lexeo Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on...